In breast cancer, loss of BCL2 has repeatedly been associated with high grade tumors and other aggressive carcinoma entities, which shows that BCL2 acts as a differentiation marker in the mammary gland [41], [42], [43]. Here, BCL2 is linked to carcinoma.